open access

Vol 53, No 6 (2022)
Short communication
Submitted: 2022-02-20
Accepted: 2022-10-12
Published online: 2022-11-07
Get Citation

Studies on platelet function during the first year of ibrutinib treatment in patients with chronic lymphocytic leukemia

Bożena Sokołowska1, Dariusz Jawniak1, Aleksandra Nowaczyńska1, Agnieszka Szymczyk2, Ewa Wąsik-Szczepanek1, Marek Hus1
DOI: 10.5603/AHP.a2022.2056
·
Acta Haematol Pol 2022;53(6):416-420.
Affiliations
  1. Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland
  2. Department of Clinical Transplantology, Medical University of Lublin, Lublin, Poland

open access

Vol 53, No 6 (2022)
SHORT COMMUNICATION
Submitted: 2022-02-20
Accepted: 2022-10-12
Published online: 2022-11-07

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

chronic lymphocytic leukemia, ibrutinib, platelet function

About this article
Title

Studies on platelet function during the first year of ibrutinib treatment in patients with chronic lymphocytic leukemia

Journal

Acta Haematologica Polonica

Issue

Vol 53, No 6 (2022)

Article type

Short communication

Pages

416-420

Published online

2022-11-07

Page views

549

Article views/downloads

69

DOI

10.5603/AHP.a2022.2056

Bibliographic record

Acta Haematol Pol 2022;53(6):416-420.

Keywords

chronic lymphocytic leukemia
ibrutinib
platelet function

Authors

Bożena Sokołowska
Dariusz Jawniak
Aleksandra Nowaczyńska
Agnieszka Szymczyk
Ewa Wąsik-Szczepanek
Marek Hus

References (15)
  1. Shatzel JJ, Olson SR, Tao DL, et al. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost. 2017; 15(5): 835–847.
  2. Wang J, Zhao A, Zhou H, et al. Risk of bleeding associated with ibrutinib in patients with B-cell malignancies: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2020; 11: 580622.
  3. Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019; 133(12): 1298–1307.
  4. Brown JR, Moslehi J, Ewer MS, et al. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis. Br J Haematol. 2019; 184(4): 558–569.
  5. Lipsky AH, Farooqui MZH, Tian X, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015; 100(12): 1571–1578.
  6. Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014; 124(26): 3991–3995.
  7. Rigg RA, Aslan JE, Healy LD, et al. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function. Am J Physiol Cell Physiol. 2016; 310(5): C373–C380.
  8. Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015; 29(4): 783–787.
  9. Pulte D, Olson KE, Broekman MJ, et al. CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia. J Transl Med. 2007; 5: 23.
  10. Alberelli MA, Innocenti I, Sica S, et al. PO-54 — clinical and laboratory characterization of platelet dysfunction caused by ibrutinib treatment in patients with chronic lymphocytic leukemia. Thromb Res. 2016; 140(Suppl 1): S196.
  11. Dmitrieva EA, Nikitin EA, Ignatova AA, et al. Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib. J Thromb Haemost. 2020; 18(10): 2672–2684.
  12. Kazianka L, Drucker C, Skrabs C, et al. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. Leukemia. 2017; 31(5): 1117–1122.
  13. Alberelli MA, Innocenti I, Autore F, et al. Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients. Haematologica. 2018; 103(3): e119–e122.
  14. Santoro RC, Falbo M, Levato L, et al. Dabigatran in ibrutinib-treated patients with atrial fibrillation and chronic lymphocytic leukemia: experience of three cases. Blood Coagul Fibrinolysis. 2021; 32(2): 159–161.
  15. Raz MA, Arnason J, Bairey O, et al. The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants. Br J Haematol. 2020; 189(2): e31–e33.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via Medica Publishers

ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone +48 58 320 94 94, fax+48 58 320 94 60,

e-mail: journals@viamedica.pl